RJR 1781

Drug Profile

RJR 1781

Alternative Names: TC 1781

Latest Information Update: 11 Oct 2004

Price : $50

At a glance

  • Originator Targacept
  • Class Small molecules
  • Mechanism of Action Dopamine release stimulants; Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 30 Sep 2004 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
  • 30 Sep 2004 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
  • 30 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top